TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A wearable device developed by MIT students in 2017 was FDA-cleared in February 2026 to help adults with essential tremor, according to MIT News. The company, Encora Therapeutics, says a clinical trial found that 78% of patients reported benefits after 90 days of home use; the available report does not give the trial size or explain the clearance’s specific conditions.
The FDA cleared Encora Therapeutics’ wrist-worn device in February 2026 to help adults with essential tremor, according to MIT News. The device began as a prototype for an MIT product-design class in 2017 and is intended to use mechanical vibration to reduce shaking.
The prototype was developed by students in MIT’s 2.009 product-design course. At a 2017 presentation, a man identified as Michael, who had Parkinson’s disease, wore the device and tried drawing a spiral, a task commonly used by doctors to assess movement. MIT News reported that his tremors decreased while the device was on and that he drew with greater precision. That demonstration was an early prototype test, not evidence of FDA clearance or a clinical trial result.
Several students continued the work, and the team became Encora Therapeutics in 2020. The company went through additional hardware iterations and clinical studies. In one trial, 78% of patients reported benefits after 90 days of home use, MIT News reported. The article does not specify the number of people in that trial, how benefits were measured, or whether the finding came from the study that supported FDA clearance.
The initial project focused on Parkinson’s disease, but the company later shifted attention to essential tremor, which also causes shaking, often in the hands. MIT News said the students’ first clinical trial, conducted in 2022 with MassGeneral Brigham, included 20 people with Parkinson’s. The report does not say whether that study contributed to the later clearance.
From MIT Prototype to Patient Use
The clearance moves a device from a classroom demonstration toward use as a treatment for adults with essential tremor. That matters to people whose shaking affects tasks such as writing or using tools, though the reported stage demonstration involved a person with Parkinson’s and should not be taken as proof of how the cleared device performs for every essential-tremor patient.
The project also illustrates the long path from a promising prototype to a regulated medical device: the team spent years refining hardware and conducting clinical work before receiving clearance. FDA clearance is the confirmed regulatory milestone in the report. It does not, by itself, establish how much the device helps across different patients, how long benefits last, or whether it is appropriate for a particular person.
Encora’s co-founder Daniel Carballo told MIT News that patient feedback has helped sustain the work. His account describes the company’s motivation; it is not independent evidence of clinical effectiveness. The study result reported by MIT News offers a separate, limited measure: a share of participants said they benefited after three months at home.
Products Worth Considering
Therabody Theragun Relief Massage Gun, 3-Speed, Navy
Bowflex SelectTech 840 Adjustable Kettlebell
BowFlex Results Series SelectTech Dumbbells
As an affiliate, we earn on qualifying purchases.
A 2017 Class Project
The idea came from a brainstorming session in MIT’s 2.009 course, where student groups generated possible product concepts. Carballo proposed a wearable that would use mechanical vibration to affect signals involved in movement. The team selected the concept by a 16-to-1 vote, even though Carballo himself opposed choosing it, according to his recollection in MIT News.
Near the end of the semester, the students met Michael, whose Parkinson’s-related hand tremors had made work as a home renovator and everyday activities difficult. The class prototype was rudimentary: Carballo described it as a foam-core box with a Raspberry Pi and wires. After Michael tried it, the team presented him using it onstage at Kresge Auditorium. Requests from audience members for the device helped motivate some students to continue developing it.
Encora first pursued a Parkinson’s application, then turned toward essential tremor. Carballo told MIT News that the team saw a greater unmet need in essential tremor and less treatment development in that area. That is his explanation for the company’s choice of focus, rather than a comparative assessment supplied in the available report.
““It’s been a long and difficult — very difficult — journey, but also very rewarding, especially when we get feedback from patients.””
— Daniel Carballo, Encora Therapeutics co-founder and vice president of strategy, quoted by MIT News
Limits of the Reported Evidence
The available MIT News account does not identify the specific FDA clearance pathway, date, device name, or conditions of use. It also does not report the trial size, the criteria used to define a patient-reported benefit, or whether the 78% result came from the evidence submitted to the FDA. Those details are needed to interpret the study finding and understand the clearance’s scope.
The report does not provide comparative results against another treatment or a control group, describe possible risks, or say how effects vary by patient. The demonstration at MIT involved one person with Parkinson’s, while the clearance described in the article is for adults with essential tremor. The two accounts concern different conditions and should not be treated as interchangeable evidence.
It is also unclear from the article when the device will be available to patients, how much it will cost, or whether insurance will cover it. No wider claims about access or clinical outcomes are confirmed in the source material.
Availability and Clinical Detail
The next practical questions concern when and where adults with essential tremor can obtain the device, what patients will pay, and whether coverage will be available. The MIT News report does not give a commercial launch schedule or provide purchasing information.
More detail about the clinical evidence and the terms of the FDA clearance would help patients and clinicians assess how the device may fit into care. The source does not announce a future study or regulatory milestone, so it is not clear what additional evidence Encora plans to publish or when.
For now, the reported development is the February clearance for adults with essential tremor, alongside the company’s account of patient-reported benefits in a 90-day home-use trial. Further information is needed to establish the size and duration of those benefits and how they apply across patients.
Key Questions
What did the FDA clear?
The FDA cleared an Encora Therapeutics wrist-worn device to help adults with essential tremor, according to MIT News. The report does not give the device’s name or the clearance’s detailed conditions of use.
How does the device work?
The device uses mechanical vibration. Its developers say the vibration sends signals through the wrist that may affect movement control. The available report does not give a detailed technical account of the cleared product.
What does the 78% figure mean?
MIT News reported that 78% of patients said they experienced benefits after 90 days of home use in one trial. The article does not state the trial size, how benefit was measured, or whether the result supported the FDA clearance.
Was the original demonstration an essential-tremor study?
No. The 2017 demonstration involved Michael, who had Parkinson’s disease. The FDA clearance described in the report is for adults with essential tremor. The stage demonstration was not presented as a clinical trial.
When can patients get the device?
The MIT News report does not say when the device will be available, what it will cost, or whether insurance will cover it.
Source: hn
